Suppr超能文献

他汀类药物与达托霉素:联合使用的安全性评估及药物相互作用可能性评估

Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.

作者信息

Golightly Larry K, Barber Gerard R, Barron Michelle A, Page Robert L

机构信息

University of Colorado Hospital, Aurora, CO, USA.

出版信息

Drug Metabol Drug Interact. 2013;28(1):49-58. doi: 10.1515/dmdi-2012-0033.

Abstract

BACKGROUND

Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury.

METHODS

Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone.

RESULTS

A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135).

CONCLUSIONS

In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.

摘要

背景

使用他汀类药物及某些相互作用的药物可能会发生急性肌肉损伤以及潜在致命的横纹肌溶解症。本研究评估了接受他汀类药物与达托霉素联合治疗的患者发生肌病的风险,达托霉素也是一种与肌肉损伤相关的药物。

方法

确定2005年7月1日至2010年6月30日期间住院并同时接受辛伐他汀或瑞舒伐他汀与达托霉素治疗的患者,并检查其病历。如果患者的病历中有肌痛证据(伴或不伴肌无力)以及继发的活动能力受损,同时肌酸激酶(CK)水平升高,则判断该患者发生了与治疗相关的肌肉损伤。将这些评估结果与仅接受他汀类药物治疗的住院患者的类似数据进行比较。

结果

共有52例患者接受了66个疗程的辛伐他汀或瑞舒伐他汀与达托霉素的联合治疗。其中,没有患者(0%)符合肌病或相关并发症诊断的证据要求。没有患者(0%)出现肌肉疼痛或不适,也没有患者出现CK水平明显升高。这些接受辛伐他汀或瑞舒伐他汀加用达托霉素治疗的患者中CK无症状升高的发生率(9%)与105例仅接受辛伐他汀或瑞舒伐他汀治疗的住院患者队列中CK升高的发生率(21%)在统计学上无显著差异(p = 0.135)。

结论

在接受辛伐他汀或瑞舒伐他汀与达托霉素联合治疗的患者中,未发现因药物相互作用导致肌肉损伤的症状或客观证据。这些发现与数据一致,表明他汀类药物和达托霉素的肌病效应是由不同且可能独特的药理机制引起的。因此,他汀类药物与达托霉素联合使用时肌肉损伤的风险似乎并不比单独使用任何一种药物时更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验